Table 6. Clinical response according to LMR-week 6 for renal cell carcinoma patients.
Response | Number (N=25, %) | Low LMR-week 6 (N=15, 60%) | High LMR-week 6 (N=10, 40%) |
---|---|---|---|
CR | 4 (16.0) | 1 (6.7) | 3 (30.0) |
PR | 4 (16.0) | 1 (6.7) | 3 (30.0) |
SD | 8 (32.0) | 7 (46.6) | 1 (10.0) |
PD | 9 (36.0) | 6 (40.0) | 3 (30.0) |
N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.